289 related articles for article (PubMed ID: 27400942)
1. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.
Lagmay JP; Krailo MD; Dang H; Kim A; Hawkins DS; Beaty O; Widemann BC; Zwerdling T; Bomgaars L; Langevin AM; Grier HE; Weigel B; Blaney SM; Gorlick R; Janeway KA
J Clin Oncol; 2016 Sep; 34(25):3031-8. PubMed ID: 27400942
[TBL] [Abstract][Full Text] [Related]
2. Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group.
Metts J; Xue W; Gao Z; Oberoi S; Weiss AR; Venkatramani R; Harrison DJ
Pediatr Blood Cancer; 2024 Jul; 71(7):e31009. PubMed ID: 38627882
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.
Isakoff MS; Goldsby R; Villaluna D; Krailo MD; Hingorani P; Collier A; Morris CD; Kolb EA; Doski JJ; Womer RB; Gorlick R; Janeway KA
Pediatr Blood Cancer; 2019 Feb; 66(2):e27524. PubMed ID: 30378256
[TBL] [Abstract][Full Text] [Related]
4. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.
Janeway KA; Barkauskas DA; Krailo MD; Meyers PA; Schwartz CL; Ebb DH; Seibel NL; Grier HE; Gorlick R; Marina N
Cancer; 2012 Sep; 118(18):4597-605. PubMed ID: 22252521
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
[TBL] [Abstract][Full Text] [Related]
6. Phase-II trials in osteosarcoma recurrences: A systematic review of past experience.
Omer N; Le Deley MC; Piperno-Neumann S; Marec-Berard P; Italiano A; Corradini N; Bellera C; Brugières L; Gaspar N
Eur J Cancer; 2017 Apr; 75():98-108. PubMed ID: 28219023
[TBL] [Abstract][Full Text] [Related]
7. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.
Hingorani P; Krailo M; Buxton A; Hutson P; Sondel PM; Diccianni M; Yu A; Morris CD; Womer RB; Crompton B; Randall RL; Teot LA; DuBois SG; Janeway KA; Gorlick RG; Isakoff MS
Eur J Cancer; 2022 Sep; 172():264-275. PubMed ID: 35809374
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.
Bishop MW; Chang YC; Krailo MD; Meyers PA; Provisor AJ; Schwartz CL; Marina NM; Teot LA; Gebhardt MC; Gorlick R; Janeway KA; Chou AJ
Pediatr Blood Cancer; 2016 Oct; 63(10):1737-43. PubMed ID: 27128693
[TBL] [Abstract][Full Text] [Related]
10. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
11. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
Arndt CA; Koshkina NV; Inwards CY; Hawkins DS; Krailo MD; Villaluna D; Anderson PM; Goorin AM; Blakely ML; Bernstein M; Bell SA; Ray K; Grendahl DC; Marina N; Kleinerman ES
Clin Cancer Res; 2010 Aug; 16(15):4024-30. PubMed ID: 20576718
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children's Oncology Group.
Oberoi S; Qumseya A; Xue W; Venkatramani R; Weiss AR
Cancer; 2024 Mar; ():. PubMed ID: 38470405
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group.
Spraker-Perlman HL; Barkauskas DA; Krailo MD; Meyers PA; Schwartz CL; Doski J; Gorlick R; Janeway KA; Isakoff MS
Pediatr Blood Cancer; 2019 Jan; 66(1):e27444. PubMed ID: 30255612
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Bond M; Bernstein ML; Pappo A; Schultz KR; Krailo M; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2008 Feb; 50(2):254-8. PubMed ID: 17262795
[TBL] [Abstract][Full Text] [Related]
15. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
[TBL] [Abstract][Full Text] [Related]
16. Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study.
Weitman S; Ochoa S; Sullivan J; Shuster J; Winick N; Pratt C; Vietti T; Harris M
J Pediatr Hematol Oncol; 1997; 19(3):187-91. PubMed ID: 9201138
[TBL] [Abstract][Full Text] [Related]
17. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma.
Guenther LM; Rowe RG; Acharya PT; Swenson DW; Meyer SC; Clinton CM; Guo D; Sridharan M; London WB; Grier HE; Ecklund K; Janeway KA
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29251406
[TBL] [Abstract][Full Text] [Related]
18. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
